ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0125

A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic
Abstract Number: 0592

A Rheumatology-Driven Protocol and Treatment Algorithm of SARS-CoV-2 Cytokine Release Syndrome and Its Associated Outcomes
Abstract Number: 0496

A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
Abstract Number: 1957

A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland
Abstract Number: 0216

A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Abstract Number: 0656

A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
Abstract Number: 1388

A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
Abstract Number: 0606

A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease
Abstract Number: 1481

A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Abstract Number: 1412

A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome
Abstract Number: 0590

A Web-Based Data Capture System Can Successfully Collect Detailed and Quantifiable Physical Therapy Intervention Data Post Total Knee Replacement
Abstract Number: 1480

Abatacept for the Treatment of IgG4-Related Disease
Abstract Number: 1991

Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Abstract Number: 0233

Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients
Abstract Number: 0569

Ability and Willingness to Utilize Telemedicine Among Rheumatology Patients – a Cross Sectional Survey

« Previous Page
1
…
3
4
5
6
7
…
139
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].